NFKB1 and Cognitive impairment: Conversely, pretreatment with Bay-11-7082, a selective inhibitor of the NLRP3 inflammasome and an NF-κB inhibitor, decreased neuronal damage and cognitive impairment, which is related to NF-κB/NLRP3 inflammasome activity [96].